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ABSTRACT 35 
Background. Bleeding is frequent and associated with impaired prognosis among patients 36 
undergoing transcatheter aortic valve replacement (TAVR). It is currently unknown whether the 37 
site of bleeding differentially influences the outcome of TAVR patients. 38 
Objective. To examine the frequency, timing, and association of access and non-access site 39 
bleeding with mortality in the setting of TAVR during long-term follow-up. 40 
Methods. We evaluated 926 consecutive patients undergoing TAVR from 2007 through 2014. 41 
Bleeding was assessed according to the Valve Academic Research Consortium (VARC-2) criteria. 42 
The primary outcome of interest was all-cause mortality up to 5 years of follow-up. 43 
Results. A total of 285 (30.7%) patients experienced at least one (minor, major or life-threatening) 44 
bleeding event up to 5 years. Compared with patients not experiencing bleeding, the adjusted 45 
risk of all-cause mortality was significantly increased among patients with access site (hazard 46 
ratio, HR, 1.34, 95% confidence intervals, CI, 1.01-1.76, p=0.04) as well as non-access site bleeding 47 
(HR 2.08, 95%CI 1.60-2.71, p<0.001). However, non-access site bleeding conferred a significantly 48 
higher risk of mortality compared with access-site bleeding (HR 1.56, 95%CI 1.12-2.18, p=0.009). 49 
At multivariable analysis, female gender was a significant correlate of access site bleeding, 50 
whereas chronic kidney disease and the STS score were significantly associated with non-access 51 
site bleeding. 52 
Conclusions. Among patients with severe aortic stenosis undergoing TAVR, access site and non-53 
access site bleeding were independently associated with an increased risk of mortality, with the 54 
greatest risk related to non-access site bleeding during long-term follow-up.  55 
Keywords: aortic stenosis; TAVR; bleeding; access site bleeding; non-access site bleeding.  56 
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Clinical Perspectives  57 
What’s known? Although transcatheter aortic valve replacement (TAVR) has been consistently 58 
associated with lower rates of bleeding events than conventional surgery, the differential 59 
prognostic impact of access site and non-access site bleeding in TAVR setting is unknown. 60 
What’s new? In this study, bleeding occurring at the access site as well as non-access site bleeding 61 
increased both the risk of mortality up to 5-year follow-up. However, non-access site bleeding 62 
conferred a greater prognostic impact than bleeding related to the access site. Female gender 63 
was associated with access site-related events, while the STS score and chronic renal failure were 64 
associated with non-access site bleeding. 65 
What’s next?  Future studies should specifically investigate novel strategies to prevent both  66 
forms of bleeding and focus on the identification of clinical subsets at higher risk of bleeding. 67 
 68 
Condensed Abstract 69 
Few data are available on the prognostic impact of access site and non-access site bleeding in 70 
patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). We 71 
evaluated 926 patients who underwent TAVR between 2007 and 2014. During 5-year follow-up, 72 
a total of 285 (30.7%) patients presented at least one bleeding episode. Bleeding events related 73 
to the access site as well as those not related to the access site increased both the risk of 74 
subsequent mortality. However, non-access site bleeding was associated with a 56% relative 75 
increase in the risk of mortality compared with access site events.  76 
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Introduction 77 
Transcatheter aortic valve replacement (TAVR) is the treatment of choice for patients with 78 
symptomatic, severe aortic stenosis deemed inoperable or at high-to-intermediate risk for 79 
conventional, surgical aortic valve replacement (SAVR).(1,2) Due to its less invasive nature, TAVR 80 
affords a substantial reduction in the risk of bleeding compared with SAVR, resulting in a 50-60% 81 
relative risk reduction of major bleeding in systematic reviews of randomized trials.(3,4) Despite 82 
this, clinically-relevant bleeding still occurs in approximately every fourth patient undergoing 83 
TAVR and confers an impaired prognosis by increasing the risk of morbidity and mortality.(5,6) 84 
However, significant heterogeneity exists as it relates to the origin of bleeding in the setting of 85 
TAVR. Indeed, hemorrhagic events can arise from either the site of vascular access and its 86 
neighboring tissues (access site bleeding) or from locations remote to the vascular access (non-87 
access site bleeding). These two entities entail distinct temporal patterns as access site bleeding 88 
is confined to the peri-procedural period, while non-access site bleeding may additionally develop 89 
during longer term follow-up. As of yet, it remains unknown whether the site of bleeding 90 
differentially influences the prognosis of patients undergoing TAVR. Therefore, the aim of the 91 
present study was to comprehensively evaluate the frequency, timing, and association of access 92 
and non-access site bleeding with long-term mortality among patients undergoing TAVR in a large 93 
prospective registry. 94 
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Methods 95 
Study population and procedure 96 
The Bern TAVR Registry is part of the Swiss TAVR Registry (NCT01368250) and prospectively 97 
collects clinical and procedural data of all consecutive patients undergoing TAVR at Bern 98 
University Hospital (Bern, Switzerland). The registry was approved by the local ethics committee 99 
and patients provided written informed consent to participate. The study complies with the 100 
declaration of Helsinki.  101 
The decision to perform TAVR was based on the evaluation of the Heart Team. Patients in the 102 
TAVR cohort received either the Medtronic CoreValve bioprosthesis (Medtronic, Minneapolis, 103 
MN, USA), the Edwards Sapien XT or Sapien 3 transcatheter heart valve (Edwards LifeSciences, 104 
Irvine, CA, USA), the Symetis Acurate TA aortic bioprosthesis (Symetis, Ecublens, Switzerland), the 105 
Portico valve (St. Jude Medical, Minneapolis, MN, USA), or the Lotus heart valve (Boston Scientific, 106 
Natick, MA, USA) through the femoral, transapical, or subclavian access, as previously 107 
described.(7) Post-procedural care consisted of heart rhythm monitoring for at least 48 hours 108 
after intervention, laboratory tests and 12-lead electrocardiogram on daily basis, and 109 
echocardiography before discharge.  110 
 111 
Data collection and study definitions 112 
In-hospital complications were closely monitored until discharge. Active follow-up was scheduled 113 
at 30 days, 12 months and yearly thereafter at clinic visits and through standardized telephone 114 
interviews. Patients were questioned about their health status, symptoms, medication and the 115 
occurrence of adverse events. A dedicated, independent clinical event committee, involving 116 
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cardiologists and cardiac surgeons, evaluated and adjudicated all adverse events including 117 
bleeding events, according to the Valve Academic Research Consortium (VARC-2) criteria 118 
(SwissTAVI CEC).(8) Accordingly, bleeding events were classified as life-threatening or disabling 119 
bleeding, major bleeding, or minor bleeding.  120 
Access site bleeding was defined as any bleeding related to access site or access-related vascular 121 
injury and hence included bleeding events originating from the puncture site as well as those 122 
arising from adjacent areas. All other events not fulfilling the criteria for access site bleeding were 123 
classified as non-access site bleeding. In case of multiple bleeding events (>1 episode), the first 124 
occurring bleeding event contributed to the analyses. The site of bleeding was independently 125 
adjudicated by 2 investigators (RP and AF), and, in case of disagreement, consensus was resolved 126 
by a third investigator (SS). All data were entered into a dedicated web-based database managed 127 
and monitored by the Clinical Trials Unit Bern (University of Bern, Switzerland). 128 
 129 
Statistical analysis 130 
Continuous variables are expressed as mean±standard deviation or median with interquartile 131 
range (IQR). Categorical variables are reported as counts and percentages. To test the association 132 
between baseline variables and the time to the occurrence of bleeding, we used a uni- and 133 
multivariable parametric Weibull survival models. 134 
The association between access and non-access site bleeding and mortality was examined using 135 
parametric Weibull survival models in which bleeding was considered as a time-varying covariate. 136 
The time in days between the index TAVR procedure and the first bleeding event triggered the 137 
status change from the non-bleeding to the bleeding group. Risk estimates are expressed as 138 
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hazard ratios (HRs) and 95% confidence intervals (CIs). Furthermore, the adjusted risk of death 139 
associated with no bleeding, access, and non-access site bleeding was calculated by including 140 
covariates with a univariable effect on all-cause mortality at level of significance less than 0.20 141 
(gender, diabetes, and Society of Thoracic Surgeons [STS] score). A subgroup analysis was 142 
conducted to evaluate the association between bleeding and mortality among patients who 143 
underwent transfemoral or transapical TAVR. Kaplan-Meier time-to-event curves (with the 144 
horizontal axis representing the time since either the index TAVR procedure or bleeding) were 145 
constructed to show the rate of mortality up to 5 years across the three study groups. Weibull 146 
survival models were finally used to examine the correlates of access and non-access site bleeding 147 
up to 5 years follow-up in the overall cohort. Variables whose p-values were less than 0.05 in 148 
univariable models were retained in the multivariable model. Statistical significance was 149 
determined by a 2-sided p <0.05. All analyses were performed with Stata statistical software 150 
(version 14.1; StataCorp LP, College Station, TX).  151 
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Results 152 
From August 2007 through June 2014, 926 consecutive patients with severe AS underwent TAVR. 153 
Baseline and procedural characteristics of the study population are summarized in Table 1 and 2. 154 
In the overall cohort, the mean age was 82.4±5.8 years and 491 patients (53%) were women. The 155 
baseline standard predictor of risk was 6.6±4.4% according to the STS score. Most patients 156 
underwent transfemoral TAVR (746 patients or 80.6%) and there was a similar implantation rate 157 
of self-expandable and balloon-expandable valve devices. Median follow-up was 2.75 years (IQR 158 
[1.17-4.40]). 159 
 160 
Frequency, Time Course, and Mortality associated with Bleeding Events 161 
As reported in Table 3, a total of 285 (30.7%) patients experienced at least one bleeding event up 162 
to 5 years, with a similar proportion between access site (145 patients or 51%) and non-access 163 
site bleeding (140 patients or 49%). Life threatening or major bleeding was observed in 224 164 
(24.2%) patients, representing thus 78.6% of all bleeding events (122 or 84% of access site and 165 
102 or 73% of non-access site bleeding events). As shown in Figure 1, the adjusted risk of mortality 166 
was significantly increased among patients who had life threatening (HR 2.30, 95%CI 1.71-3.08, 167 
p<0.001) or major bleeding (HR 1.36, 95%CI 1.02-1.81, p=0.034) compared those who did not 168 
experience a bleeding event. 169 
The incidence of access and non-access site bleeding during follow-up is shown in Figure 2. 170 
Approximately 80% of all bleeding events occurred within the first 30 days after TAVR. However, 171 
while all access site bleeding events arose within the first 30 days after the index TAVR, late 172 
bleeding (>30 days) accounted for 40% of non-access site bleeding. The gastrointestinal tract was 173 
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the most frequent identifiable site of non-access site bleeding. In 53 patients (5.7%), more than 1 174 
bleeding event was observed. 175 
 176 
Clinical and Procedural Characteristics 177 
In univariable analyses (Table 1), we found higher risk of bleeding in older patients, those with a 178 
lower body mass index, anemic patients, and those with chronic renal failure. As reported in Table 179 
2, bleeding was associated with different prescription of antithrombotic therapy at discharge. 180 
Table 4 describes antithrombotic therapy throughout follow-up. There was an increasing 181 
proportion of patients treated with either single antiplatelet therapy or oral anticoagulant 182 
starting from 1-year, while dual antiplatelet therapy and the combination of oral anticoagulant 183 
with single or dual antiplatelet therapy were less commonly prescribed during long-term follow-184 
up. 185 
 186 
Impact of Type of Bleeding on Mortality in the Overall Cohort 187 
As shown in Figure 3, the rate of all-cause mortality up to 5 years follow-up associated with no 188 
bleeding, access site, and non-access site life-threatening or major bleeding amounted to 49%, 189 
58.7%, and 72.6%, respectively.  190 
Crude and adjusted analyses on mortality provided consistent results (Figure 4 and 5). As shown 191 
in Figure 4, the risk of mortality up to 5 years of follow-up was significantly increased in patients 192 
experiencing access site (adjusted HR 1.34, 95%CI 1.01-1.76, p=0.04) or non-access site bleeding 193 
(adjusted HR 2.08, 95%CI 1.60-2.71, p<0.001) compared with those not having any bleeding. 194 
However, non-access site bleeding conferred a significantly higher risk of mortality compared 195 
with access-site bleeding (adjusted HR 1.56, 95%CI 1.12-2.18, p=0.009) (Figure 5).  196 
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The association between each specific site of bleeding and mortality is reported in Table 3. 197 
Intracranial, pericardial and gastro-intestinal bleeding as well as bleeding in the setting of chronic 198 
anemia or trauma significantly increased the risk of mortality compared with no bleeding.  199 
Packed red blood cells (PRBC) transfusions were used in 130 (46%) patients in the overall cohort, 200 
in 64 (44%) patients with access site bleeding events, and in 66 (49%) patients with non-access 201 
site bleeding events. The effect of packed red blood cells (PRBC) transfusion on the association 202 
between type of bleeding and mortality is reported in Online Table 1. Among patients with access 203 
site bleeding, the risk of mortality remained low when PRBC transfusions were not required, 204 
whereas it was significantly increased in patients needing PRBC transfusions. Among patients with 205 
non-access site bleeding, the risk of mortality was significantly increased irrespective of the use 206 
of PRBC transfusion, but the magnitude of this association was more pronounced in case of 207 
transfusions. There was a strong association between bleeding severity and the use of PRBC 208 
transfusion (Online Table 2). 209 
 210 
Impact of Bleeding on Mortality in the Transfemoral and the Transapical cohort 211 
As shown in Online Figure 1, in the transfemoral cohort (n=746) access-site bleeding was 212 
associated with numerically increased risk of mortality (adjusted HR 1.33, 95%CI 0.99-1.79, 213 
p=0.056). However, non-access site bleeding significantly increased the risk of mortality 214 
compared with no bleeding (adjusted HR 2.51, 95%CI 1.84-3.43, p<0.001), yielding to a higher risk 215 
of mortality compared with access site bleeding (adjusted HR 1.87, 95%CI 1.28-2.72, p=0.001, 216 
Online Figure 2). Results were consistent in the analysis restricted to life-threatening or major 217 
bleeding events (Online Figure 1 and 2). 218 
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Among patients who underwent transapical TAVR (n=165), neither access-site bleeding (adjusted 219 
HR 1.58, 95%CI 0.69-3.61, p=0.27) nor non-access site bleeding (adjusted HR 1.52, 95%CI 0.69-220 
3.61, p=0.27) were associated with a significantly higher risk of death compared with no bleeding 221 
(Online Figure 3). Consequently, there was no significant difference in the risk of mortality 222 
associated with non-access vs. access-site bleeding (adjusted HR 1.23, 95%CI 0.48-3.14, p=0.67) 223 
(Online Figure 4). 224 
 225 
Correlates of Life-Threatening or Major Bleeding  226 
Variables associated with access and non-access site bleeding are reported in Table 5. In the 227 
multivariable analysis, female gender was the only correlate of access site bleeding, whereas 228 
chronic kidney disease and the STS score were significant correlates of non-access site bleeding 229 
after TAVR. Antithrombotic therapy was not associated with bleeding events at univariable 230 
analysis. Moreover, antithrombotic therapy during follow-up was not associated with post-231 
discharge, non-access site bleeding events (Online Table 3). 232 
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Discussion 233 
The salient findings of this study, which evaluated the prognostic impact of bleeding in relation 234 
to its source among 926 patients undergoing TAVR, can be summarized as follows:  235 
1. Bleeding after TAVR was observed in approximately 30% of patients up to 5 years, with a 236 
similar proportion between access site and non-access site events (51% and 49%). However, 237 
about 40% of non-access site bleeding events emerged more than 30 days after the index 238 
procedure; 239 
2. Both access-site and non-access site bleeding conveyed an increased risk of all-cause 240 
mortality. Nevertheless, patients who experienced non-access site bleeding incurred a higher 241 
risk of mortality than those who experienced bleeding at the access site; 242 
3. This pattern was consistently observed among patients undergoing transfemoral TAVR, but 243 
not in those undergoing transapical TAVR which, however, constituted less than 20% of the 244 
overall population; 245 
4. Female gender was a correlate of access site bleeding, while chronic kidney disease and the 246 
STS score were correlates of non-access site bleeding.  247 
 248 
Patients with severe aortic stenosis feature a heightened risk of spontaneous bleeding due to 249 
advanced age, numerous comorbidities, and impaired primary hemostasis with type IIA von 250 
Willebrand’s disease.(9,10) Such predisposition, together with a greater invasiveness of the 251 
procedure and a frequent development of acquired coagulopathy during cardiopulmonary 252 
bypass, accounts for the high incidence of bleeding complications among patients undergoing 253 
SAVR.(11) Over the past years, TAVR emerged as a less invasive alternative to SAVR and has been 254 
associated with lower rates of life-threatening or major bleeding.(12-15) Indeed, a variety of 255 
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parameters of bleeding severity, including the magnitude of blood loss, hemoglobin decline, and 256 
number of transfused blood products, has been consistently improved by TAVR compared with 257 
SAVR across several studies.(16,17) As a result, the reduced risk of bleeding related to TAVR is 258 
considered one of the key mechanisms explaining the TAVR-related survival benefit proven in 259 
recent randomized trials.(12-15) Nevertheless, bleeding in TAVR continues to occur in a relatively 260 
high proportion – 30% in our study – and adversely affects prognosis as highlighted by several 261 
studies revealing that early as well as late bleeding events are linked with an increased risk of 262 
subsequent mortality.(17-21)  263 
 264 
To the best of knowledge, this is the first study evaluating the clinical impact of bleeding according 265 
to its source in the setting of TAVR and therefore extends prior observations in several ways. Our 266 
results showed a steadily increasing rate of mortality amounting to 49%, 59%, and 73% among 267 
TAVR patients experiencing no bleeding, access site, and non-access site bleeding, respectively. 268 
Although both access site and non-access site bleeding adversely impacted prognosis, non-access 269 
site resulted in a more than 1.5-fold higher risk of death compared with access-site bleeding in 270 
the transfemoral cohort. These findings parallel those observed in the field of percutaneous 271 
coronary intervention, where non-access related major bleeding complications have a 272 
significantly greater impact on mortality compared with access-site complications.(21-23) A 273 
possible reason for this analogy is that non-access site bleeding is a multifactorial event that 274 
encapsulates the patient risk profile as well as coexisting comorbidities, and whose risk is 275 
longitudinal and extends over time, which is not the case of access site events that typically occur 276 
in the aftermath of the index procedure. Accordingly, in our study, chronic kidney disease and the 277 
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STS score, which reflects the burden of age and comorbidities, resulted correlates of non-access 278 
site bleeding. 279 
Because the risk of mortality was increased for both access site and non-access site bleeding, 280 
preventive strategies of either form of bleeding should be pursued to improve the safety profile 281 
of TAVR and patient prognosis. Importantly, as the association between bleeding source and 282 
mortality was consistently observed in the transfemoral cohort, the use of this route of access 283 
may not suffice to offset the detrimental effects of bleeding complications. In this context, 284 
procedural antithrombotic therapy and refinements in vascular access technique, closure of the 285 
access site, and the delivery sheath profile play a major role in the prevention of access site 286 
bleeding. Yet, the optimal antithrombotic regimen in TAVR remains to be well defined as recently 287 
highlighted by a randomized trial showing a similar risk of major bleeding with direct thrombin 288 
inhibition with bivalirudin against unfractioned heparin at 48 hours after TAVR.(24) Moreover, 289 
there is evidence that downsizing the introducer sheath profiles from 22 or 24 F to 18-19 F, and 290 
further to 14-18 F have resulted in a lower incidence of vascular complications, which are 291 
etiologically associated with access site bleeding.(25-29) Unsurprisingly, female gender was 292 
associated with access site bleeding, which is keeping with multiple studies showing a higher risk 293 
of early bleeding and vascular complications among women compared with men.(30) The 294 
mechanisms are likely multifactorial and include a lower body surface area, older age, and small 295 
femoral arteries in women undergoing TAVR.(31,32) 296 
For the prevention of non-access site bleeding, strategies should be targeted to both short- and 297 
long-term follow-up, as 60% of bleeding events occurred within 30 days and the remaining 40% 298 
thereafter. During the mid- and long-term phase after TAVR, the selection of oral antithrombotic 299 
therapy appears of paramount importance.(5) Nevertheless, there is still limited evidence to 300 
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inform clinical decision in this regard, and currently at least three randomized trials are 301 
investigating different antithrombotic regimens after TAVR (NCT02247128, NCT02556203, and 302 
NCT02664649).(33,34) Obviously, the incidence of bleeding during the long-term follow-up points 303 
to the individual risk-profile of the patient and thus is less dependent from procedure-related 304 
factors, as also suggested by our multivariable analysis. In this respect, additional risk factors for 305 
late bleeding included low hemoglobin, atrial fibrillation, the presence of moderate or severe 306 
paravalvular leak in an analysis of 2,401 TAVR patients.(17) 307 
 308 
The present study should be interpreted in light of the following limitations. First, the study 309 
population was based on the experience of a single, tertiary care center and therefore the results 310 
might not be extrapolated to other centers with different procedural experience as well as patient 311 
selection. Second, the lack of a greater prognostic impact of non-access site compared with access 312 
site bleeding among patients who underwent transapical TAVR should be carefully interpreted in 313 
view of the relatively small number of patients included in this cohort. The likely underpowered 314 
analysis should be therefore considered when potential different mechanisms underlying access-315 
site bleeding are considered in the setting of transapical TAVR. Third, although the risk of 316 
mortality for access site and non-access site bleeding was adjusted for relevant covariates, there 317 
might have been residual confounders due to unmeasured factors. In this respect, data on sheath 318 
size were not available in the registry. Fourth, patients experiencing non-access site bleeding 319 
presented a higher risk profile and, therefore, bleeding events may represent in some cases a 320 
marker of disease rather than a true mediator of mortality. Fifth, although antithrombotic therapy 321 
did not influence the risk of post-discharge non-access site bleeding, results have to be carefully 322 
interpreted given the non-randomized nature of our study. Finally, the 5 years follow-up was not 323 
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available in all patients and, as a consequence, the long-term sequelae of non-access site bleeding 324 
might have been partly underestimated.  325 
 326 
In conclusion, bleeding complications after TAVR were frequent by occurring in nearly 1 out of 3 327 
patients up to 5 years follow-up. Access site and non-access site bleeding were associated with 328 
an increased risk of mortality, but non-access site bleeding conferred a significantly greater 329 
magnitude of risk than access site-related events. Female gender was a correlate of access site 330 
bleeding, while chronic kidney disease and the STS score were correlates of non-access site 331 
bleeding. Futures studies focused on preventive strategies for either form of bleeding are 332 
warranted and might have an important clinical implications in the care of patients with severe 333 
aortic stenosis undergoing transcatheter aortic valve implantation. 334 
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Figure Legends 435 
Figure 1. Effect of bleeding on mortality up to 5-year follow-up. 436 
 437 
Figure 2. Incidence of bleeding over time as proportion of the entire population. 438 
 439 
Figure 3. Cumulative time-to-event curves showing the rate of mortality up to 5 years among 440 
patients without bleeding events, patients with access site bleeding, and patients with non-access 441 
site bleeding. Bleeding is defined as life-threatening or major bleeding. 442 
 443 
Figure 4. Unadjusted and adjusted risk estimates for access site and non-access site bleeding 444 
versus no bleeding in the overall cohort. Among patients without any bleeding, there were 227 445 
deaths with 1764.9 person-years, corresponding to an annual mortality rate of 12.9%. 446 
 447 
Figure 5. Unadjusted and adjusted risk estimates for access site vs. non-access site bleeding in the 448 
overall cohort. 449 
 450 
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TABLE 1. Baseline clinical characteristics 451 
              
  Overall  Patients with Bleeding Events 
Patients without 
Bleeding Events p-value  
Patients with 
access site 
bleeding 
Patients with 
non-access site 
bleeding 
  N = 926  N = 285 N = 641   N = 145 N = 140 
          
Age (years) 82.4 ±  5.8  83.0 ±  5.3 82.1 ±  6.0 0.027  83.4 ±  4.8 82.5 ±  5.8 
Female gender, n (%) 491 (53)  161 (56) 330 (51) 0.45  90 (62%) 71 (51%) 
BMI, (kg/cm2) 26.3 ±  5.1  25.6 ±  4.6 26.6 ±  5.2 0.004  25.7 ±  4.9 25.5 ±  4.4 
Diabetes mellitus, n (%) 244 (26%)  84 (29%) 160 (25%) 0.13  41 (28%) 43 (31%) 
Dyslipidemia, n (%) 588 (63%)  170 (60%) 418 (65%) 0.21  87 (60%) 83 (59%) 
Hypertension, n (%) 788 (85%)  237 (83%) 551 (86%) 0.66  119 (82%) 118 (84%) 
Previous MI, n (%)  150 (16%)  45 (16%) 105 (16%) 0.90  22 (15%) 23 (16%) 
Previous CABG, n (%) 97 (11%)  21  (8%) 76 (13%) 0.71  9  (7%) 12  (9%) 
Previous PCI, n (%) 255 (28%)  75 (26%) 180 (28%) 0.52  39 (27%) 36 (26%) 
Previous stroke, n (%) 40  (4%)  5  (2%) 35  (6%) 0.52  3  (2%) 2  (2%) 
Peripheral vascular disease, n (%) 164 (18%)  56 (20%) 108 (17%) 0.82  23 (16%) 33 (24%) 
COPD, n (%) 144 (16%)  48 (17%) 96 (15%) 0.47  20 (14%) 28 (20%) 
Anemia, n (%) 539 (58%)  170 (60%) 369 (58%) 0.04  78 (54%) 92 (66%) 
Hemoglobin (g/l) 120.5 ± 16.6  119.2 ± 16.9 121.1 ± 16.4 0.005  120.6 ± 17.4 117.7 ± 16.4 
Chronic kidney disease, n (%) 648 (70%)  219 (77%) 429 (67%) 0.017  110 (76%) 109 (78%) 
Atrial fibrillation, n (%) 301 (33%)  92 (32%) 209 (33%) 0.18  47 (32%) 45 (32%) 
LVEF, (%)  53.4 ± 15.1  53.7 ± 14.6 53.2 ± 15.3 0.58  53.6 ± 15.2 53.8 ± 14.0 
Aortic valve area, (cm2)  0.6 ±  0.2  0.6 ±  0.2 0.7 ±  0.2 0.54  0.6 ±  0.3 0.6 ±  0.2 
Mean transvalvular gradient, (mmHg)  42.3 ± 17.3  43.3 ± 17.4 41.9 ± 17.3 0.72  43.5 ± 17.4 43.0 ± 17.6 
Logistic EuroSCORE, (%) 21.8 ± 13.3  23.2 ± 13.6 21.2 ± 13.1 0.06  23.3 ± 14.4 23.0 ± 12.9 
STS score, (%) 6.6 ±  4.4  7.1 ±  4.8 6.4 ±  4.1 0.004  7.2 ±  4.5 7.1 ±  5.2 
Antithrombotic therapy before TAVR     0.88    
24 
  
Single antiplatelet therapy, n (%) 390 (49%)  125 (52%) 265 (48%)   67 (53%) 58 (50%) 
Dual antiplatelet therapy, n (%) 156 (20%)  43 (18%) 113 (20%)   22 (17%) 21 (18%) 
Oral anticoagulant, n (%) 172 (22%)  53 (22%) 119 (21%)   24 (19%) 29 (25%) 
Oral anticoagulant plus single or dual 
antiplatelet therapy, n (%) 80 (10%)  21  (9%) 59 (11%)   14 (11%) 7  (6%) 
None, n (%) 125 (14%)  41 (14%) 84 (13%)   18 (12%) 23 (17%) 
         
Depicted are means ± SD or counts (%). P-values are derived from Weibull survival models. Chronic kidney disease was defined a glomerular filtration 452 
rate <60 ml/min/1.73 m2.BMI: body mass index. COPD: chronic obstructive pulmonary disease. EuroSCORE: European System for Cardiac Operative 453 
Risk Evaluation. LVEF: left ventricular ejection fraction. SAPT: single antiplatelet therapy. STS: Society of Thoracic Surgeons.  454 
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TABLE 2. Procedural characteristics and antithrombotic therapy at discharge 455 
  Overall  Patients with Bleeding Events 
Patients without 
Bleeding Events p-value  
Patients with 
access site 
bleeding 
Patients with 
non-access site 
bleeding 
  N = 926  N = 285 N = 641   N = 145 N = 140 
          
General anesthesia, n (%) 319 (34.4%)  113 (39.6%) 206 (32.1%) 0.065  44 (30.3%) 69 (49.3%) 
Residual moderate/severe aortic 
regurgitation, n (%) 105 (11.3%)  40 (14.0%) 65 (10.1%) 0.087  19 (13.1%) 21 (15.0%) 
Concomitant PCI, n (%) 143 (15.4%)  51 (17.9%) 92 (14.4%) 0.188  26 (17.9%) 25 (17.9%) 
Permanent Pacemaker Implantation, 
n (%) 129 (20.4%)  35 (21.2%) 94 (20.2%) 0.231  15 (18.1%) 20 (24.4%) 
In-hospital stay after TAVR, (days) 9.36 ±  4.86  10.52 ±  6.38 8.95 ±  4.12 <0.001  9.64 ±  5.28 11.41 ±  7.24 
Access      0.575    
Transfemoral, n (%) 746 (80.6%)  224 (78.6%) 522 (81.4%)   130 (89.7%) 94 (67.1%) 
Transapical, n (%) 165 (17.8%)  55 (19.3%) 110 (17.2%)   12  (8.3%) 43 (30.7%) 
Transsubclavian, n (%) 12  (1.3%)  6  (2.1%) 6  (0.9%)   3  (2.1%) 3  (2.1%) 
Other, n (%) 3  (0.3%)  0  (0.0%) 3  (0.5%)   0  (0.0%) 0  (0.0%) 
Device     0.404    
Medtronic CoreValve, n (%) 429 (47.1%)  131 (47.1%) 298 (47.1%)   79 (56.0%) 52 (38.0%) 
Edwards Sapien XT, n (%) 380 (41.7%)  129 (46.4%) 251 (39.7%)   55 (39.0%) 74 (54.0%) 
Edwards Sapien 3, n (%) 51  (5.6%)  6  (2.2%) 45  (7.1%)   3  (2.1%) 3  (2.2%) 
Symetis Acurate, n (%) 39  (4.3%)  10  (3.6%) 29  (4.6%)   2  (1.4%) 8  (5.8%) 
SJM Portico, n (%) 3  (0.3%)  1  (0.4%) 2  (0.3%)   1  (0.7%) 0  (0.0%) 
BSC Lotus, n (%) 9  (1.0%)  1  (0.4%) 8  (1.3%)   1  (0.7%) 0  (0.0%) 
Anti-thrombotic therapy at discharge     0.003    
Single antiplatelet therapy, n (%) 43  (4.8%)  18  (6.7%) 25  (4.0%)   10  (7.3%) 8  (6.1%) 
Dual antiplatelet therapy, n (%) 576 (64.6%)  164 (61.2%) 412 (66.1%)   88 (64.2%) 76 (58.0%) 
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Oral anticoagulant, n (%) 45  (5.1%)  14  (5.2%) 31  (5.0%)   8  (5.8%) 6  (4.6%) 
Oral anticoagulant plus single or 
dual antiplatelet therapy, n (%) 227 (25.5%)  72 (26.9%) 155 (24.9%) 
  31 (22.6%) 41 (31.3%) 
None, n (%) 5  (0.6%)  2  (0.7%) 3  (0.5%)   1  (0.7%) 1  (0.8%) 
Depicted are means ± SD or counts (%). P-values are derived from Weibull survival models. 456 
PCI: percutaneous coronary intervention. TAVR: transcatheter aortic valve replacement.  457 
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TABLE 3. Bleeding severity and location during follow-up 458 
 459 
 
Bleeding severity  All bleeding events 
  Minor 
bleeding 
Major 
bleeding 
Life 
threatening 
bleeding 
 No.  events 
Adjusted HR of bleeding 
vs. no bleeding (95%CI) P-value 
        
Access site bleeding 23 (38%) 80 (59%) 42 (47%)  145 (51%) 1.34 (1.01-1.76) 0.04 
Non-access site bleeding 38 (62%) 55 (41%) 47 (53%)  140 (49%) 2.08 (1.60-2.71) <0.001 
Intracranial 0  (0%) 0  (0%) 8  (9%)  8  (3%) 3.34 (1.24 - 9.00) 0.017 
Intraocular 0  (0%) 0  (0%) 1  (1%)  1  (0%) 2.98 (0.42 - 21.38) 0.28 
Gastrointestinal 12 (20%) 25 (19%) 10 (11%)  47 (16%) 2.54 (1.68 - 3.85) <0.001 
Genito-urinary 4  (7%) 5  (4%) 1  (1%)  10  (4%) 0.70 (0.24 - 1.98) 0.50 
Epistaxis 4  (7%) 1  (1%) 0  (0%)  5  (2%) 0.97 (0.24 - 3.94) 0.97 
Chronic anemia 0  (0%) 3  (2%) 1  (1%)  4  (1%) 4.38 (1.63 - 11.78) 0.003 
Pericardial 0  (0%) 2  (1%) 12 (13%)  14  (5%) 4.49 (2.44 - 8.27) <0.001 
Pulmonary 1  (2%) 1  (1%) 5  (6%)  7  (2%) 0.77 (0.19 - 3.11) 0.71 
Trauma 4  (7%) 2  (1%) 0  (0%)  6  (2%) 4.38 (1.63 - 11.81) 0.003 
Other surgery 1  (2%) 0  (0%) 4  (4%)  5  (2%) 2.29 (0.57 - 9.22) 0.24 
Other 12 (20%) 16 (12%) 5  (6%)  33 (12%) 1.62 (0.99 - 2.66) 0.055 
        
        
Analysis includes the first bleeding event at patient-level (each patient counted only once). Hazard ratios (HRs) with 95% confidence intervals (95%Cis) 460 
are derived by Weibull’s survival models in which patients without bleeding events was considered the control group. HR are adjusted for gender, 461 
diabetes, and the Society of Thoracic Surgeons score (see Methods). 462 
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TABLE 4. Antithrombotic therapy throughout follow-up 463 
 464 
              
Antithrombotic therapy 
throughout follow-up 
1 month 1-Year 2-Year 3-Year 4-Year 5-Year 
N = 893 N = 831 N = 699 N = 494 N = 307 N = 190 
              
Single antiplatelet therapy, n (%) 79 (10%) 328 (46%) 266 (57%) 256 (60%) 116 (57%) 85 (57%) 
Dual antiplatelet therapy, n (%) 495 (60%) 167 (23%) 44  (9%) 29  (7%) 19  (9%) 10  (7%) 
Oral anticoagulant, n (%) 57  (7%) 108 (15%) 89 (19%) 96 (22%) 50 (25%) 31 (21%) 
Oral anticoagulant plus single or 
dual antiplatelet therapy, n (%) 182 (22%) 99 (14%) 54 (12%) 35  (8%) 12  (6%) 9  (6%) 
None, n (%) 8  (1%) 17  (2%) 11  (2%) 11  (3%) 7  (3%) 15 (10%) 
              
              
 465 
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TABLE 5. Multivariable analysis for life-threatening or major bleeding events 466 
 467 
 468 
  
HR (95%CI) P-value 
 Overall cohort   
Access site bleeding   
Female gender 2.59 (1.10-6.13) 0.030 
Non-access site bleeding   
Chronic kidney disease 1.99 (1.02-3.87) 0.043 
STS score (per 1% increase) 1.05 (1.00-1.10) 0.047 
   
 469 
Chronic kidney disease was defined a glomerular filtration rate <60 ml/min/1.73 m2. Candidate variables: 470 
Age, female gender, body mass index, diabetes mellitus, previous coronary artery bypass graft, previous 471 
percutaneous coronary intervention, previous stroke, peripheral vascular disease, anemia, renal failure, 472 
coronary artery disease, atrial fibrillation, aortic regurgitation ≥2 after TAVR, concomitant coronary 473 
revascularization, aortic valve area, STS score. Anti-thrombotic therapy at in-hospital admission was 474 
included as candidate variable for both access site and non-access site bleeding. Antithrombotic therapy at hospital 475 
discharge was additionally included as candidate variable for the analysis of non-access site bleeding.  476 
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Online Appendix 
 
Online Table 1. Association between access-site and non-access site bleeding with mortality 
among patients who received packed red blood cell transfusions (PRBCs) or not. 
 
Online Table 2. Use of packed red blood cell transfusions (PRBCs) according to bleeding 
location and severity. 
 
Online Table 3. Association between antithrombotic therapy and the risk of late post-
discharge bleeding. 
 
Online Figure 1. Unadjusted and adjusted risk estimates for access site and non-access site 
bleeding versus no bleeding in the transfemoral cohort. Among patients without any 
bleeding, there were 180 deaths with 1480.1 person-years, corresponding to an annual 
mortality rate of 12.1%. 
 
Online Figure 2. Unadjusted and adjusted risk estimates for access site vs. non-access site 
bleeding in the transfemoral cohort.  
 
Online Figure 3. Unadjusted and adjusted risk estimates for access site and non-access site 
bleeding versus no bleeding in the transapical cohort. Among patients without any bleeding, 
there were 47 deaths with 284.8 person-years, corresponding to an annual mortality rate of 
16.5%. 
 
Online Figure 4. Unadjusted and adjusted risk estimates for access site vs. non-access site 
bleeding in the transapical cohort. 
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Online Table 1. Association between access-site and non-access site bleeding with mortality among patients who received packed red blood cell 
transfusions (PRBCs) or not. 
 
  Access site bleeding vs.  
no bleeding 
 Non-access site bleeding  
vs. no bleeding 
 Access-site vs.  
non-access site bleeding 
 
  HR (95% CI) P-value  HR (95% CI) P-value  HR (95% CI) P-value  
           
Unadjusted           
Patients receiving PRBCs           
Any bleeding  1.75 (1.22 - 2.52) 0.002  2.50 (1.80 - 3.47) <0.001  1.42 (0.91 - 2.24) 0.13  
Life threatening or major bleeding  1.86 (1.29 - 2.70) 0.001  2.54 (1.81 - 3.57) <0.001  1.36 (0.85 - 2.18) 0.19  
Minor bleeding  0.88 (0.22 - 3.55) 0.86  1.96 (0.63 - 6.12) 0.25  2.22 (0.37 - 13.27) 0.38  
Patients without PRBCs           
Any bleeding  1.08 (0.74 - 1.56) 0.69  1.99 (1.41 - 2.82) <0.001  1.85 (1.16 - 2.96) 0.01  
Life threatening or major bleeding  1.05 (0.70 - 1.59) 0.81  2.00 (1.30 - 3.07) 0.002  1.90 (1.08 - 3.34) 0.027  
Minor bleeding  1.20 (0.57 - 2.55) 0.63  2.01 (1.19 - 3.40) 0.009  1.67 (0.68 - 4.11) 0.26  
           
Adjusted           
Patients receiving PRBCs           
Any bleeding  1.53 (1.06 - 2.21) 0.022  2.59 (1.86 - 3.60) <0.001  1.67 (1.05 - 2.65) 0.03  
Life threatening or major bleeding  1.62 (1.11 - 2.36) 0.011  2.62 (1.86 - 3.69) <0.001  1.62 (1.00 - 2.60) 0.048  
Minor bleeding  0.78 (0.19 - 3.17) 0.73  2.17 (0.69 - 6.80) 0.18  2.77 (0.46 - 16.68) 0.27  
Patients without PRBCs           
Any bleeding  1.12 (0.77 - 1.62) 0.55  1.68 (1.18 - 2.39) 0.004  1.54 (0.95 - 2.49) 0.082  
Life threatening or major bleeding  1.13 (0.75 - 1.71) 0.56  1.57 (1.00 - 2.47) 0.048  1.39 (0.77 - 2.51) 0.27  
Minor bleeding  1.11 (0.52 - 2.35) 0.80  1.86 (1.10 - 3.15) 0.021  1.68 (0.68 - 4.14) 0.26  
           
Analysis includes the first bleeding event at patient-level (each patient counted only once). CI: confidence intervals. HR: hazard ratio.   
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Online Table 2. Use of packed red blood cell transfusions (PRBCs) according to bleeding 
location and severity. 
              
  Life threatening or 
major or minor 
bleeding (N =285) 
  Bleeding severity  
    
Life threatening 
(N=89) 
Major 
(N=135) 
Minor 
(N=61) P-value 
Access or non-access  
site bleeding 130 (46%)  66 (75%) 55 (41%) 9 (15%) <0.001 
Access site bleeding 64 (44%)   32 (76%) 27 (34%) 5 (22%) <0.001 
Non-access site bleeding 66 (49%)   34 (74%) 28 (52%) 4 (11%) <0.001 
   
Data show the use of packed red blood cell transfusions according to bleeding location and severity. Analysis includes 
the first bleeding event at patient-level (each patient counted only once). 
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Online Table 3. Association between antithrombotic therapy and the risk of late post-
discharge bleeding. 
 
  
HR (95% CI) P-value   
Antithrombotic therapy   0.351 
Single antiplatelet therapy 1 (reference)   
Dual antiplatelet therapy 0.77 (0.32 - 1.86) 0.56 
Oral anticoagulant 1.04 (0.32 - 3.39) 0.946 
Oral anticoagulant plus single  
or dual antiplatelet therapy 
1.65 (0.68 - 3.96) 0.267 
None 0.71 (0.09 - 5.65) 0.75 
Antithrombotic therapy considered as time varying covariate. CI: 
confidence intervals. HR: hazard ratio. 
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